



Antimalarials Market Information Methodologies Consensus Meeting Feedback from 25th March (Day 1)

26th March 2008, MMV Offices, Geneva

Curing Malaria Together www.mmv.org



Medicines for Malaria Venture

Ongoing studies



- Large number of studies currently underway / about to start
- Significant overlap in certain countries – the meeting has helped to flag these. Partners can share information
- Degree of commonality in approach
 - WHO / HAI methodology served as important starting point
 - Surveying all antimalarials at baseline
 - Census approach
 - Inclusion of formal and informal sectors important in malaria
 - Importance of comparative antimalarials and essential medicines
- Outstanding issues:
 - Initial sampling: PSI = LQAS, HAI = 6 districts, MMV = 6 districts

Outstanding Issues Identified Day 1



- Approaches to sampling (baseline and monitoring)
- Improving monitoring systems: sampling and frequency
- Price: should this be the international reference price (WHO/HAI) or local currency (MMV)
- Measuring Volumes in the private sector
- Incentives to prevent stock outs (public) and to carry product (private)

Monitoring & Evaluation: Some Key Issues



- Distinguish between monitoring (regular data) & Evaluation
- How frequent should monitoring surveys take place?
- What should be included:
 - Sampling for outlets?
 - Sampling of products – all or a subset?
 - Link supply and demand sides to show trends and shifts

Use of Data: Some Key Issues



- Feedback is critical to ensure use of the data
- Who is audience?
- Who is stakeholders to involve in studies?
- How to ensure partners are fully involved from the start

Volumes: Some Key Issues



- Approach from top and bottom of supply chain
 - Importer data and retail audit
- Retail Audits / Record keeping and recall in private sector
 - Survey on the basis of 2 week recall?
 - How regular should audits be?
- RI and IMS health already collect some of this data
- Mainly more formal outlets (pharmacy) – how can this be adapted for the antimalarials market
- How can you encourage national authorities / importers to share data?
- Importance of triangulating data
- CLEAR INTEREST IN MOVING TO NEXT PHASE

Further Questions to Consider – Day 2



- **Sampling**

Questions: **was is optimal approach in the absence of sample frame?**

- Impact of the difference in sampling approaches (WHO/HAI, MMV, PSI)
- Sampling of outlets – census as baseline to understand the ‘population of outlets and the relative importance of different sectors’
- Sampling for monitoring – how? Re-sample or outlet monitoring?
- Which medicines should be surveyed during monitoring?
- Link of sampling to PV safety data gathering?
- Mapping and sampling at all levels in the supply chain

- **Equity**

Questions: **where do lower SES currently access treatment, what products?
do ACTs reach the poor?
to what extend will a subsidised product reach the poor?**

- Agreement on equity indicators
- How can we measure equity in the supply side?
- How can we measure equity in the demand side?
- Specific additional aspects to add to the current studies?
- How does changes in the market link to shifts in public / private treatment provision?



Further Questions to Consider – Day 2



- **Price Components**

Questions: **how is the price coming down for different product types is a price decrease (subsidy) passed on to patients?**

- Validating price components information
- Using the WHO/HAI components methodology
- Determinants of mark ups? How to measure these?
- Experience and recommendations

- **Volumes**

Questions: **how to gather info. on volumes of all antimalarials?**

- What information already exists – what can we tap into?
- How can we obtain information on private sector volumes?
- What systems / incentives are required to improve data (2 week recall..)
- How can we measure shift in the market over time?
- Specific additional aspects to add to the current studies?



Further Questions to Consider – Day 2



- **Perceptions**

Questions: **how do perceptions of products influence uptake?**

how do perceptions of products influence supply?

- How do we measure consumer perceptions of the products, (drug failure, perceived stock outs in public sector, health seeking behaviour, use of traditional medicines)
- Provider perceptions of the products – what influences supply decisions?
- What can be included to ensure minimum quality of care for safety support?
- How does the shift in price impact public / private provision?

- **Dissemination of results**

Questions: **how can we ensure the data gets used?**

- who is the audience : different needs for different audiences...
- what do they need / what will they do with it
- how to include stakeholders fully (from the start)
- how should it be presented?

Next Steps



- Group work: 3 groups focus on 1 issue for 2 hours
- Recommendation on approaches: Feedback
- Agreement on core info / further consensus required
- Agreement on next steps following this meeting
 - Information sharing
 - Measuring market size (volumes)